alexa New Challenges For IFN Therapy
ISSN: 2155-9597

Journal of Bacteriology & Parasitology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

International Congress on Bacteriology & Infectious Diseases
November 20-22, 2013 DoubleTree by Hilton Baltimore-BWI Airport, MD, USA

Ahmed Lasfar
ScientificTracks Abstracts: J Bacteriol Parasitol
DOI: 10.4172/2155-9597.S1.002
IFN-α is widely used in clinic for the treatment of viral infection and cancer. However, its use remains problematic for two main reasons: 1) low efficacy and 2) numerous and significant side effects. With the discovery of IFN-λ, new challenges for the IFN therapy are expected in the future. Although IFN-λ and classical IFN-α utilize distinct receptor complexes for signaling, both types of IFNs activate similar intracellular signaling pathways and biological activities, including the ability to induce antiviral state in cells. However, in contrast to IFN-α, the response to IFN-λ is highly cell-type specific. Only epithelial cells and to a lesser extent some immune cells respond to IFN-λ. This particular pattern of response is controlled by the differential expression of the IFN-λ receptor, which, in contrast to IFN-α, should result in limited side effects in patients. Recently, we have demonstrated that both IFN-λ and IFN-α exert comparable antitumor activity. However their antitumor mechanisms were distinct. Interestingly, when IFN-λ and IFN-α are combined, significant improvement of the antitumor effect was observed. Therefore, the use of a new IFN therapy, based on the combination of IFN-α and IFN-λ may help overcome the main obstacles of the current IFN therapy.
Ahmed Lasfar has completed his Ph.D. in Immunology from Paris University and Pasteur Institute and postdoctoral studies from University of Medicine and Dentistry of New Jersey. He is assistant Professor at Rutgers University. He has published more than 20 papers and book chapters in the field of interferon. He is serving as an editorial board member for numerous journals.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version